DOCSLIB.ORG

The Business Case for Building the Janssen Brand

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The Business Case for Building the Janssen Brand Challenges in Drug Development for Other Viruses Than HIV or Hepatitis: Influenza Thomas Kakuda, PharmD Scientific Director, Clinical Pharmacology Rich Infectious Disease Therapeutics and Vaccines Portfolio PRODUCTS IN REGISTRATION SELECTED EARLY- TO APPROVED PRODUCTS OR PLANNED FILINGS 2017-2021 MID-STAGE PIPELINE1 FILED Hepatitis B Darunavir STR (D/C/F/TAF) • JNJ-5948/NVR3-778 (HBV capsid assembly modulator) • HIV (EU) • JNJ-6379 (HBV capsid assembly modulator) • JNJ-0440 (HBV capsid assembly modulator) • JNJ-0535 (HBV therapeutic vaccine) PLANNED FILINGS • JNJ-4964 (TLR Agonist) (US) Darunavir STR (D/C/F/TAF) Respiratory Syncytial Virus • HIV (US)* • JNJ-8678 (RSV fusion inhibitor) Rilpivirine • JNJ-7184 (RSV non-nuc polymerase inhibitor) • rilpivirine/dolutegravir STR • JNJ-8194/VAC18194 (RSV pediatric vaccine) • rilpivirine/cabotegravir long-acting maintenance therapy** Influenza PREZCOBIX®/REZOLSTA® • JNJ-5806/AL-794 (Influenza PA inhibitor) (EU) • HIV pediatric exclusivity • JNJ-7445 (Influenza antibody) SIRTURO® • Pediatric TB** Dengue JNJ-4178 (3DAA) • JNJ-8359 (NS4B inhibitor)** • Hepatitis C HIV Pimodivir (JNJ-3872) • JNJ-9220/VAC89220 (HIV vaccine prophylactic) • Influenza A • JNJ-9220/VAC89220 (HIV vaccine w/ MVA boost therapeutic) Lumicitabine (JNJ-1575) • Pediatric RSV infection Filovirus • Adult RSV infection • VAC69120 (Filovirus multivalent vaccine) • Adult hMPV Poliomyelitis JNJ-1860 (ExPEC vaccine) • Bacterial infection • JNJ-2348 (Sabin IPV vaccine) Monovalent Ebola Vaccine submitted to WHO for Emergency Use Assessment and Listing (EUAL) VAC18193 (RSV vaccine) Cervical Cancer • RSV elderly • JNJ-1623/VAC81623 (HPV vaccine) New Molecular Entities Line Extensions 1. Potential filings up to 2027, non-risk adjusted. Products marketed worldwide, but not all products in all markets/regions. * Indicates In Registration **Indicates assets for Global Public Health Note: Filings/approvals are in the US or EU, unless otherwise noted. This information is accurate as of the date hereof to the best of Johnson & Johnson’s knowledge. The Company assumes no obligation to update this information. Flu (not the same as a cold or “stomach flu”) • Symptoms • Complications • High fever • Bacterial/viral pneumonia • Sore throat • Cardiac failure • Headache • Respiratory failure • Myalgia • Myositis • Cough • Encephalopathy (rare) • Fatigue • At-risk populations • Very young • Elderly • Immunocompromised • Heart or lung disease, diabetics, … Influenza Causes Significant Morbidity and Mortality 1B* cases annually worldwide, with 250,000-500,000 deaths; 10-20% of the population in developed countries infected each season Associated Deaths Indication Per Year In the U.S. each season: Influenza Up to 56,000 Colon Cancer 49,190 25M* total cases Pancreatic Cancer 41,780 12M attend medical specialist 390,000 hospitalizations Breast Cancer 40,890 Prostate Cancer 26,120 Leukemia 24,400 Lymphoma 21,270 Skin Cancer 13,650 “Spanish” influenza pandemic of 1918 – 1919 caused ~50M deaths worldwide * M = Millions, B = Billions World Health Organization, 2016; Kostova et al., PLOS ONE, 2013; Zhou et al., Clinical Infectious Diseases, 2012; CDC MMWR Aug. 27, 2010; Sleeman, K. et al., AAC, 2010; American Cancer Association, Cancer Facts & Figures, 2016; Taubenberger, Jeffery K., and Morens, David M., "1918 Influenza: The Mother of All Pandemics." Emerging Infectious Diseases 12.1, 2006: 15-22. Web. Orthomyxovirus • Influenza types A, B, C and D • Negative-strand RNA virus • Only replicates in epithelial cells • 8 segments of ssRNA • Type A involved in pandemics • Codes for >10 proteins • Type B and C cause milder disease Influenza A subtypes • Hemaglutinin (H) • Neuraminidase (N) • Binds sialic acid-containing receptors • Cleaves sialic acid (neuraminic acid) Subtype Human Swine Horse Bird Subtype Human Swine Horse Bird H1 + + – + N1 + + + + H2 + – – + N2 + + – + H3 + + + + N3 – – – + H4 – – – + N4 – – – + H5 + – + + N5 – – – + H6 – – – + N6 – – – + H7 + – + + N7 – – + + H8-H17 – – – + N8 – – + + N9 + – – + Transmission • Nomenclature • Animal resevoir • e.g. A(H1N1)pdm09 = influenza type A with H1 and N1 antigens that caused the pandemic “swine flu” in 2009 • Low Pathogenicity Avian Influenza (LPAI) • High Pathogenicity Avian Influenza (HPAI) • B/Yamagata and B/Victoria lineages (no subtypes) • Antigenic drift vs antigenic shift • Drift: point mutations → seasonal flu • Shift: major reassortment → pandemic • H7N9 considered most likely to start the next pandemic Seasonal disease (in temperate climates) • Usually occur during winter (October to March) • Close proximity (e.g. schools, nursing homes, office,…) • Coughing and sneezing aerosolizes the virus • 100,000 to 1,000,000 virions per droplet • Virus can survive in colder temperature https://www.cdc.gov/mmwr/volumes/66/wr/mm6606a2.htm Prophylaxis and treatments are available but have limitations Vaccines Antivirals 1. Vaccines are strain specific – have to be administered each 1. Short window of administration – antivirals have to be year and susceptible to strain mismatch which renders them administered within 48 hours of becoming symptomatic to ineffective be effective. 2. Imperfect protection – seasonal vaccines are 70-90% effective in preventing influenza infection in healthy adults; 30-40% 2. Drug resistance over time – spontaneous mutations in effective in elderly patients who live in nursing homes and in the virus render treatment completely ineffective against immunocompromised patients, and <50% effective among those some flu strains sometimes in only one season. An older with one or more high-risk conditions, poor vaccine response in class of M2 ion channel inhibitors have been rendered young children necessitates two doses almost completely ineffective across the G7 regions due to 3. Require lag time to full protection – body develops antibodies drug resistance. against the viral strain about two weeks after vaccination2 3. Effectiveness is not well defined, especially in high- 4. Manufactured through a long and complicated production risk population – studies have shown Tamiflu and other cycle – manufactured in eggs, not easily scalable in case of a neuraminidase inhibitors to have a modest effect in pandemic, limited production capacity (limited antigen yield) reducing flu symptoms and infectivity but there is 5. Are administered intramuscularly – at least 15% of insufficient published data to know if they reduce unvaccinated patients mention needle-phobia as a reason for complications. not being vaccinated1 Influenza: Critical Pathways and Targets ENDOCYTOSIS ENTRY FUSION Prioritized Biological Pathways: • Inhibition of Viral Replication (polymerase) • Pimodivir* (JNJ-3872) – PB2 inhibitor • JNJ-5806 (AL-794) – PA inhibitor • Inhibition of Virus Attachment/Fusion REPLICATION • JNJ-7445 – Multi-domain influenza CLEAVAGE antibody Neuraminidase inhibitors (NAIs)1 1. Multiple NAIs approved: Oseltamivir (PO), Zanamivir (IN), Peramivir (IV), Laninamivir (IN) * Licensed from Vertex Pharmaceuticals, Inc. Federal funds from the Office of the Assistant Secretary for Preparedness and Response, BARDA, under Contract Number HHSO100201500014C. Influenza challenge study • Healthy volunteer study (Phase 1b) • Not considered an efficacy trial but helps determine antiviral activity or prophylaxis • Limited clinical sites with experience • GMP influenza • Reproducible? • Limitations (to extrapolating to real-world infections) • Attenuated strain • Infection rate ~50% (exclude vaccinated subjects) • Less symptoms • Very controlled environment • Drug administered within symptom-onset AL-794-801 influenza viral challenge study in healthy volunteers: ITT-I Viral Kinetics Placebo BID (N=14) AL-794 50 mg BID (N=10) AL-794 150 mg BID (N=18) 10 TCID50/mL) Mean (+SE) Viral Load (LogLoad(+SE) Viral Mean LLOD Observations less than two are not represented Time from first dose (Days) BID = Twice Daily Phase 2-3 trials • Prophylaxis vs treatment • Different indications • Uncomplicated vs complicated • Trials in complicated patients are more difficult • High-risk (e.g. elderly) • Underlying disease (e.g. cardiac or respiratory) • Immunocompromised • No study has demonstrated efficacy in hospitalized patients • Unclear regulatory path • Active-controlled non-inferiority trial not possible • Add-on superiority trial (investigational drug + SoC vs SoC; SoC is off-label use) • Blinded, randomized, dose- or duration-response trial TOPAZ . Phase 2b, randomized, double-blind, placebo-controlled, parallel-group, dose-response, multicenter study . Participants were randomized 1:1:1:1 to one of four treatments: Dosing for 5 days, twice-daily Pimodivir 300 mg Pimodivir 600 mg Combination Pimodivir Placebo + OST pimodivir 300 mg + OST pimodivir 600 mg + OST pimodivir 600 mg + OST pimodivir placebo + OST placebo placebo 75 mg placebo . Participants were followed for 14 days total BID, twice-daily; OST, oseltamivir Janssen Research & Development Primary Endpoint: Viral load over time by qRT-PCR (log10 copies/mL) [FAS] Viral load assay LOQ = 4.0 log10 copies/mL, LOD = 3.48 log10 copies/mL. Results <LOQ and >LOD (“target detected”) are imputed with 3.75 log10 copies/mL; results <LOD (“target not detected”) are imputed with 0 log10 copies/mL Janssen Research & Development Primary Endpoint: Viral load (qRT-PCR)[FAS] Comparison Pimodivir Pimodivir Pimodivir Pimodivir 300 mg vs placebo 600 mg vs placebo 600 mg+ 600 mg+ OST 75 mg vs OST 75 mg vs placebo pimodivir 600 mg Change in AUC viral -3.6 -4.5 -8.6 -4.1 loada (-7.1; -0.1)
Load more

Recommended publications
  • Optumrx Brand Pipeline Forecast
    RxOutlook® 1st Quarter 2019 OptumRx brand pipeline forecast Route of Regulatory Estimated Specialty Orphan Drug name Generic name Company Drug class Therapeutic use administration status release date drug drug 2019 Possible launch date Ophthalmological DS-300 DS-300 Eton undisclosed SC Filed NDA 2019 unknown N disease anti-sclerostin Evenity romosozumab Amgen Osteoporosis SC Filed NDA 2/2019 Y N monoclonal antibody tetrahydrofolate iclaprim iclaprim Motif Bio Bacterial infections IV Filed NDA 2/13/2019 Y Y dehydrogenase inhibitor tazarotene/ IDP-118 Valeant retinoid/ corticosteroid Psoriasis TOP Filed NDA 2/15/2019 N N halobetasol adenosine deaminase Mavenclad cladribine Merck/ Teva resistant Multiple sclerosis PO Filed NDA 2/15/2019 Y N deoxyadenosine analog Lotemax Gel loteprednol Valeant corticosteroid Ocular inflammation OP Filed NDA 2/25/2019 N N Nex Gen etabonate turoctocog alfa glyco-PEGylated factor NN-7088 Novo Nordisk Hemophilia IV/SC Filed BLA 2/27/2019 Y N pegol VIII derivative selective sphingosine-1 BAF-312 siponimod Novartis phosphate receptor Multiple sclerosis PO Filed NDA 3/1/2019 Y N agonist midazolam midazolam UCB benzodiazepine Seizures Intranasal Filed NDA 3/1/2019 N Y (USL-261) XeriSol glucagon Xeris glucagon analog Diabetes mellitus SC Filed NDA 3/1/2019 N N Glucagon optum.com/optumrx 1 RxOutlook® 1st Quarter 2019 Route of Regulatory Estimated Specialty Orphan Drug name Generic name Company Drug class Therapeutic use administration status release date drug drug dopamine receptor JZP-507 sodium oxybate Jazz Narcolepsy
    [Show full text]
  • Microorganisms-07-00521-V2.Pdf
    microorganisms Review Are Community Acquired Respiratory Viral Infections an Underestimated Burden in Hematology Patients? Cristian-Marian Popescu 1,* , Aurora Livia Ursache 2, Gavriela Feketea 1 , Corina Bocsan 3, Laura Jimbu 1, Oana Mesaros 1, Michael Edwards 4,5, Hongwei Wang 6, Iulia Berceanu 7, Alexandra Neaga 1 and Mihnea Zdrenghea 1,7,* 1 Department of Hematology, Iuliu Hatieganu University of Medicine and Pharmacy, 8 Babes str., 400012 Cluj-Napoca, Romania; [email protected] (G.F.); [email protected] (L.J.); [email protected] (O.M.); [email protected] (A.N.) 2 The Faculty of Veterinary Medicine, University of Agricultural Sciences and Veterinary Medicine, Calea Mănăs, tur 3-5, 400372 Cluj-Napoca, Romania; [email protected] 3 Department of Pharmacology, Toxicology and Clinical Pharmacology, Iuliu Ha¸tieganuUniversity of Medicine and Pharmacy, 400337 Cluj-Napoca, Romania; [email protected] 4 National Heart and Lung Institute, St Mary’s Campus, Imperial College London, London W2 1PG, UK; [email protected] 5 Medical Research Council (MRC) and Asthma UK Centre in Allergic Mechanisms of Asthma, London W2 1PG, UK 6 School of Medicine, Nanjing University, 22 Hankou Road, Nanjing 210093, China; [email protected] 7 Department of Hematology, Ion Chiricuta Oncology Institute, 34-36 Republicii Street, 400015 Cluj-Napoca, Romania; [email protected] * Correspondence: [email protected] (C.-M.P.); [email protected] (M.Z.) Received: 8 October 2019; Accepted: 31 October 2019; Published: 2 November 2019 Abstract: Despite a plethora of studies demonstrating significant morbidity and mortality due to community-acquired respiratory viral (CRV) infections in intensively treated hematology patients, and despite the availability of evidence-based guidelines for the diagnosis and management of respiratory viral infections in this setting, there is no uniform inclusion of respiratory viral infection management in the clinical hematology routine.
    [Show full text]
  • Current and Novel Approaches in Influenza Management
    Review Current and Novel Approaches in Influenza Management Erasmus Kotey 1,2,3 , Deimante Lukosaityte 4,5, Osbourne Quaye 1,2 , William Ampofo 3 , Gordon Awandare 1,2 and Munir Iqbal 4,* 1 West African Centre for Cell Biology of Infectious Pathogens (WACCBIP), University of Ghana, Legon, Accra P.O. Box LG 54, Ghana; [email protected] (E.K.); [email protected] (O.Q.); [email protected] (G.A.) 2 Department of Biochemistry, Cell & Molecular Biology, University of Ghana, Legon, Accra P.O. Box LG 54, Ghana 3 Noguchi Memorial Institute for Medical Research, University of Ghana, Legon, Accra P.O. Box LG 581, Ghana; [email protected] 4 The Pirbright Institute, Ash Road, Pirbright, Woking, Surrey GU24 0NF, UK; [email protected] 5 The University of Edinburgh, Edinburgh, Scotland EH25 9RG, UK * Correspondence: [email protected] Received: 20 May 2019; Accepted: 17 June 2019; Published: 18 June 2019 Abstract: Influenza is a disease that poses a significant health burden worldwide. Vaccination is the best way to prevent influenza virus infections. However, conventional vaccines are only effective for a short period of time due to the propensity of influenza viruses to undergo antigenic drift and antigenic shift. The efficacy of these vaccines is uncertain from year-to-year due to potential mismatch between the circulating viruses and vaccine strains, and mutations arising due to egg adaptation. Subsequently, the inability to store these vaccines long-term and vaccine shortages are challenges that need to be overcome. Conventional vaccines also have variable efficacies for certain populations, including the young, old, and immunocompromised.
    [Show full text]
  • Study Protocol
    NCT03376321 Janssen Research & Development * Clinical Protocol A Phase 3 Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-care Treatment in Adolescent, Adult, and Elderly Hospitalized Patients With Influenza A Infection Protocol 63623872FLZ3001; Phase 3 AMENDMENT 2 JNJ-63623872-ZCD Pimodivir *Janssen Research & Development is a global organization that operates through different legal entities in various countries. Therefore, the legal entity acting as the sponsor for Janssen Research & Development studies may vary, such as, but not limited to Janssen Biotech, Inc.; Janssen Products, LP; Janssen Biologics, BV; Janssen-Cilag International NV; Janssen Pharmaceutica NV; Janssen, Inc; Janssen Sciences Ireland UC; or Janssen Research & Development, LLC. The term “sponsor” is used throughout the protocol to represent these various legal entities; the sponsor is identified on the Contact Information page that accompanies the protocol. This study will be conducted under US Food & Drug Administration IND regulations (21 CFR Part 312). EudraCT NUMBER: 2017-002156-84 Status: Approved Date: 11 June 2019 Prepared by: Janssen Research & Development, a division of Janssen Pharmaceutica NV EDMS number: EDMS-ERI-121941709, 10.0 GCP Compliance: This study will be conducted in compliance with Good Clinical Practice, and applicable regulatory requirements. Confidentiality Statement The information in this document contains trade secrets and commercial information that are privileged or confidential and may not be disclosed unless such disclosure is required by applicable law or regulations. In any event, persons to whom the information is disclosed must be informed that the information is privileged or confidential and may not be further disclosed by them.
    [Show full text]
  • Repurposing Nucleoside Analogs for Human Coronaviruses
    ANTIVIRAL AGENTS crossm Repurposing Nucleoside Analogs for Human Coronaviruses Keivan Zandi,a,b Franck Amblard,a,b Katie Musall,a,b Jessica Downs-Bowen,a,b Ruby Kleinbard,a,b Adrian Oo,a,b Dongdong Cao,c Bo Liang,c Olivia O. Russell,a,b Tamara McBrayer,a,b Leda Bassit,a,b Baek Kim,a,b Raymond F. Schinazia,b aCenter for AIDS Research, Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, USA Downloaded from bChildren’s Healthcare of Atlanta, Atlanta, Georgia, USA cDepartment of Biochemistry, Emory University School of Medicine, Atlanta, Georgia, USA ABSTRACT Coronavirus disease 2019 (COVID-19) is a serious illness caused by se- vere acute respiratory syndrome coronavirus 2 (SARS-CoV-2 or CoV-2). Some reports claimed certain nucleoside analogs to be active against CoV-2 and thus needed con- firmation. Here, we evaluated a panel of compounds and identified novel nucleoside analogs with antiviral activity against CoV-2 and HCoV-OC43 while ruling out others. http://aac.asm.org/ Of significance, sofosbuvir demonstrated no antiviral effect against CoV-2, and its triphosphate did not inhibit CoV-2 RNA polymerase. KEYWORDS SARS-CoV-2, HCoV-OC43, antiviral agents, nucleoside analogs, remdesivir, sofosbuvir, emtricitabine, lamivudine, COVID-19, Coronaviridae oronavirus disease 2019 (COVID-19) has emerged as a global pandemic with Csignificant morbidity and mortality caused by the severe acute respiratory syn- on December 16, 2020 by guest drome coronavirus 2 (SARS-CoV-2 or CoV-2). CoV-2-infected individuals usually develop mild to severe flulike symptoms, whereas other individuals (particularly the elderly harboring underlying chronic health complications, such as diabetes and heart disease, or immunocompromised individuals) are particularly prone to develop severe to fatal clinical outcomes (1, 2).
    [Show full text]
  • Respiratory Syncytial Virus
    RSV Respiratory syncytial virus RSV (Respiratory syncytial virus) is a leading cause of acute respiratory infections. RSV can exploit host immunity and cause a strong inflammatory response that leads to lung damage and virus dissemination. There is a single RSV serotype with two major antigenic subgroups, A and B. RSV is a non-segmented negative-sense single-stranded enveloped RNA virus that belongs to the family of Paramyxoviridae, genus Pneumovirus, subfamily Pneumovirinae. Its 10 genes encode 11 proteins since two overlapping open reading frames in the M2 mRNA yield two distinct matrix proteins, M2-1 and M2-2. The viral envelope contains three proteins, the G glycoprotein, the fusion (F) glycoprotein, and the small hydrophobic (SH) protein. The RSV virus comprises five other structural proteins, the large (L) protein, nucleocapsid (N), phosphoprotein (P), matrix (M), and M2-1, and two non-structural proteins (NS1 and NS2). www.MedChemExpress.com 1 RSV Inhibitors Ac-CoA Synthase Inhibitor1 ALS-8112 Cat. No.: HY-104032 Cat. No.: HY-12983 Ac-CoA Synthase Inhibitor1 is a potent, reversible ALS-8112 is a potent and selective respiratory acetate-dependent acetyl-CoA synthetase 2 syncytial virus (RSV) polymerase inhibitor. The (ACSS2) inhibitor with an IC50 of 0.6 µM. Ac-CoA 5'-triphosphate form of ALS-8112 inhibits RSV Synthase Inhibitor1 inhibits the respiratory polymerase with an IC50 of 0.02 μM. syncytial virus (RSV). Purity: 99.23% Purity: 99.97% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 50 mg, 100 mg Amentoflavone ent-11β-Hydroxyatis-16-ene-3,14-dione (Didemethyl-ginkgetin) Cat.
    [Show full text]
  • Study Initiation Q4 2017 - 18
    Study Initiation Q4 2017 - 18 Reasons for Research Ethics Integrated Research Date Site Non- Date of First Date Site . Date Site HRA Approval Date Site Date Site Ready Benchmark delay Committee Application System Name of Trial Confirmed By Confirmation Patient Reasons for Delay Comments Invited Selected Date Confirmed To Start Met correspond Reference Number Number Sponsor Status Recruited to: HRA pack was received prematurely PLATO - PersonaLising Anal cancer radioTherapy dOse - 16/YH/0157 204585 21/07/2016 12/04/2017 20/07/2016 30/06/2017 13/06/2017 Please Select... 14/08/2017 21/06/2017 Yes A - Permissions delayed/denied from sponsor. Delays with site capacity Both Incorporating Anal Cancer Trials (ACT) ACT3, ACT4 and ACT5 and capability review. MAnagement of high bleeding risk patients post bioresorbable A - Site documentation delays. Rare 17/LO/0108 221119 polymer coated STEnt implantation with an abbReviated versus 23/12/2016 10/04/2017 10/04/2017 29/03/2017 04/04/2017 Please Select... 30/05/2017 01/08/2017 No A - Permissions delayed/denied NHS Provider patient group prolonged DAPT regimen – MASTER DAPT Delays by sponsor - portfolio adoption awaited and then site pharmacy concerns remained unresolved by Cereal Bar or oral supplementation with tablets to increase serum Site declined to Site Not 16/LO/1130 187152 01/02/2017 05/05/2017 01/11/2016 D - Sponsor Delays sponsor and it was decided to close Sponsor folate in young pregnant women participate Confirmed BSUH as a site on the 17/08/17, therefore we did not open as a site for this study 70 Day target date missed due to sponsor delays with devices and delays with MHRA & HRA Approvals.
    [Show full text]
  • Study Protocol
    NCT03381196 Janssen Research & Development * Clinical Protocol A Phase 3 Randomized, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-care Treatment in Adolescent, Adult, and Elderly Non-hospitalized Subjects With Influenza A Infection who Are at Risk of Developing Complications Protocol 63623872FLZ3002; Phase 3 AMENDMENT 1 JNJ-63623872-ZCD Pimodivir *Janssen Research & Development is a global organization that operates through different legal entities in various countries. Therefore, the legal entity acting as the sponsor for Janssen Research & Development studies may vary, such as, but not limited to Janssen Biotech, Inc.; Janssen Products, LP; Janssen Biologics, BV; Janssen-Cilag International NV; Janssen Pharmaceutica NV; Janssen, Inc; Janssen Sciences Ireland UC; or Janssen Research & Development, LLC. The term “sponsor” is used throughout the protocol to represent these various legal entities; the sponsor is identified on the Contact Information page that accompanies the protocol. This study will be conducted under US Food & Drug Administration IND regulations (21 CFR Part 312). EudraCT NUMBER: 2017-002217-59 Status: Approved Date: 9 February 2018 Prepared by: Janssen Research & Development, a division of Janssen Pharmaceutica NV EDMS number: EDMS-ERI-121910908, 6.0 GCP Compliance: This study will be conducted in compliance with Good Clinical Practice, and applicable regulatory requirements. Confidentiality Statement The information in this document contains trade secrets and commercial information that are privileged or confidential and may not be disclosed unless such disclosure is required by applicable law or regulations. In any event, persons to whom the information is disclosed must be informed that the information is privileged or confidential and may not be further disclosed by them.
    [Show full text]
  • To Download a Copy of Agencyiq's COVID-19 Development Tracker
    Development tracker: The drugs and vaccines in development for COVID-19 The pharmaceutical and biopharmaceutical industry is scrambling to put products into development to potentially treat, cure or prevent COVID-19 infections. Based on a review by AgencyIQ of ClinicalTrials.gov, company announcements and media reports, there are at least 140 medical product candidates in various stages of testing to assess their potential effects against COVID-19 or SARS-CoV-2, the virus which causes the condition. Some have already been approved and are being assessed for their potential to treat COVID, while others are being repurposed from other late-stage development pipelines. Others are still in the very early stages of development and have not yet been tested in humans. Based on evidence from recent studies, the chances of clinical success are low. Of all drugs for infectious diseases that enter Phase 1 testing, just 26.7% go on to obtain approval. Just 31.6% of vaccines that enter Phase 1 testing go on to obtain approval. The size of the development pipeline and interest in COVID-19 may indicate that several of these products will go on to obtain approval, but the safety and efficacy of these products is far from guaranteed. As companies try to bring whatever compounds they have into clinical testing, it’s possible that few, if any, of these products will ultimately prove safe or effective. Highlights: 95+ 45+ 24+ 40+ Therapeutic medical Vaccines in development Products already approved Products already in clinical products in development for other indications development (6 vaccines, 34 therapies) Last updated 8 April 2020.
    [Show full text]
  • Usage of Antivirals and the Occurrence of Antiviral Resistance in Norway 2018
    REPORT 2019 Usage of Antivirals and the Occurrence of Antiviral Resistance in Norway 2018 RAVN Resistensovervåking av virus i Norge Resistance against Antivirals in Norway Usage of Antivirals and the Occurrence of Antiviral resistance in Norway 2018 RAVN Resistensovervåkning av virus i Norge Resistance against antivirals in Norway 2 Published by the Norwegian Institute of Public Health Division of Infection Control and Environmental Health Department for Infectious Disease registries October 2019 Title: Usage of Antivirals and the Occurrence of Antiviral Resistance in Norway 2018. RAVN Ordering: The report can be downloaded as a pdf at www.fhi.no Graphic design cover: Fete Typer ISBN nr: 978-82-8406-032-3 Emneord (MeSH): Antiviral resistance Any usage of data from this report should include a specific reference to RAVN. Suggested citation: RAVN. Usage of Antivirals and the Occurrence of Antiviral Resistance in Norway 2018. Norwegian Institute of Public Health, Oslo 2019 Resistance against antivirals in Norway • Norwegian Institute of Public Health 3 Table of contents Introduction _________________________________________________________________________ 4 Contributors and participants __________________________________________________________ 5 Sammendrag ________________________________________________________________________ 6 Summary ___________________________________________________________________________ 8 1 Antivirals and development of drug resistance ______________________________________ 10 2 The usage of antivirals in Norway
    [Show full text]
  • Unconventional Viral Gene Expression Mechanisms As Therapeutic Targets
    Review Unconventional viral gene expression mechanisms as therapeutic targets https://doi.org/10.1038/s41586-021-03511-5 Jessica Sook Yuin Ho1,3, Zeyu Zhu1,3 & Ivan Marazzi1,2 ✉ Received: 8 June 2020 Accepted: 22 March 2021 Unlike the human genome that comprises mostly noncoding and regulatory sequences, Published online: 19 May 2021 viruses have evolved under the constraints of maintaining a small genome size while expanding the efciency of their coding and regulatory sequences. As a result, viruses Check for updates use strategies of transcription and translation in which one or more of the steps in the conventional gene–protein production line are altered. These alternative strategies of viral gene expression (also known as gene recoding) can be uniquely brought about by dedicated viral enzymes or by co-opting host factors (known as host dependencies). Targeting these unique enzymatic activities and host factors exposes vulnerabilities of a virus and provides a paradigm for the design of novel antiviral therapies. In this Review, we describe the types and mechanisms of unconventional gene and protein expression in viruses, and provide a perspective on how future basic mechanistic work could inform translational eforts that are aimed at viral eradication. Expression of a gene in the human genome is a multistep and heavily (for example, alternative splicing) or use unique strategies. Here we regulated process that resembles a production line. Protein-coding describe the diverse ways by which viral genomes give rise to genes and genes are transcribed almost exclusively by RNA polymerase II (RNAPII). proteins that deviate from the canonical framework of human genes, During transcription, quality-control checkpoints are implemented to restricting our analyses to eukaryotes and their viruses.
    [Show full text]
  • Current and Future Antiviral Medications to Treat Influenza: Mechanisms of Action
    University of Louisville Journal of Respiratory Infections REVIEW ARTICLE Current and Future Antiviral Medications to Treat Influenza: Mechanisms of Action Julio A. Ramirez1* DOI: 10.18297/jri/vol3/iss1/9 Received Date: February 1, 2019 Accepted Date: March 13, 2019 https://ir.library.louisville.edu/jri/vol3/iss1/ Affiliations: 1University of Louisville, Divison of Infectious Diseases, School of Medicine This original article is brought to you for free and open access by ThinkIR: The University of Louisville’s Institutional Repository. It has been accepted for inclusion in The University of Louisville Journal of Respiratory Infections by an authorized editor of ThinkIR. For more information, please contact [email protected]. Recommended Citation: Ramirez, Julio A. (2019) “Current and Future Antiviral Medications to Treat Influenza: Mechanisms of Action,” The University of Louisville Journal of Respiratory Infections: Vol. 3 : Iss. 1 , Article 9. Introduction Due to significant research efforts in the field of influenza cells (Figure 1: Attachment). Since sialic acids are abundant therapy, in the near future we will have a series of new antivirals in membranes of human epithelial cells, the virus has multiple to treat patients with influenza. Most likely, hospitalized receptors to attach. The binding of the hemagglutinin to sialic patients with influenza pneumonia as well as other severe acid triggers the next step of viral entry into the cell. forms of influenza will be managed with combination antiviral therapy. During the selection of antivirals, it will be important Step 2. Endocytosis of the influenza virus for physicians to have a clear understanding of the mechanisms of action of anti-influenza medications.
    [Show full text]